Nanobiotix (NASDAQ:NBTX) Shares Gap Up – Should You Buy?

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) shares gapped up prior to trading on Thursday . The stock had previously closed at $20.06, but opened at $21.05. Nanobiotix shares last traded at $21.3790, with a volume of 789 shares trading hands.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on NBTX. HC Wainwright reaffirmed a “buy” rating on shares of Nanobiotix in a research note on Tuesday, November 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a report on Thursday. Leerink Partners reaffirmed an “outperform” rating on shares of Nanobiotix in a research report on Tuesday, November 25th. Finally, Wall Street Zen raised shares of Nanobiotix to a “hold” rating in a research report on Saturday, October 25th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $11.00.

Nanobiotix Stock Down 2.1%

The company’s 50 day moving average price is $21.56 and its 200-day moving average price is $16.19.

Hedge Funds Weigh In On Nanobiotix

An institutional investor recently bought a new position in Nanobiotix stock. Optiver Holding B.V. bought a new position in shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) during the third quarter, according to its most recent filing with the SEC. The fund bought 5,356 shares of the company’s stock, valued at approximately $101,000. Hedge funds and other institutional investors own 38.81% of the company’s stock.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.